Lineage Cell Therapeutics Inc. — Proxy Solicitation & Information Statement 2023

Aug 2, 2023

The board of directors of Lineage Cell Therapeutics, Inc. is soliciting the enclosed proxy for use at Lineage 2023 annual meeting of shareholders to b false

������' �� ��������� ����	2 380
.LINEAGE CELL THERAPEUTICS, INC
Corporation no: 876343	10834
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	02/08/2023
	www.isa.gov.il			www.tase.co.il				Reference:	2023-02-088443	Time of broadcast: 10:33 10:33

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onThe board of directors of Lineage Cell Therapeutics, Inc. is soliciting the enclosed proxy for use at Lineage 2023 annual meeting of shareholders to be held at 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 on September 6, 2023 at 8:00 a.m. PacificTime.

DEF_14A__isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: -1	Date of revision of form structure: 20/06/2023
Address: HARBOR BAY PARKWAY 1301 , ALAMEDA 94502   CALIFORNIA , U.S.A Tel: 5105213390 , Fax: 5105213389
E-mail address: info@biotimeinc.com   Company site: biotimeinc.com
Previous names of reporting entity: .BIOTIME, INC
Name of the Signatory: Gerzi SHNEOR Ilan Position of Signatory in the reporting corporation: Legal Adviser Name of Employer Company: PEARL COHEN ZEDEK LATZER BARATZ
Address: Derech Menachem Begin 121 , Tel Aviv 6701203 Telephone: 03-3039000 Facsimile: E-mail: igerzi@pearlcohen.com 1
U.S.A